Skip to content
Back to recalls
Drug FDA Class II Ongoing cGMP deviation

BENLYSTA (belimumab) for injection, 400 mg/20 mL vial, Rx only, NDC 49401-102-01, GSK.

Mckesson Medical-Surgical Inc. Corporate Office Published Jul 30, 2025

Risk level

Class II

May cause a temporary or reversible health problem; slight chance of serious harm.

Severity score 50/100

What should you do?

  • Check whether you have this product, using the lot codes, UPCs, and dates listed below.
  • Do not eat, serve, or sell the affected product.
  • Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
  • Contact Mckesson Medical-Surgical Inc. Corporate Office or your place of purchase with questions, and see the source record below for full details.
Reason for recall

CGMP Deviations; potential temperature excursions due to transit delays

Hazards

Temperature Excursion · primary

Affected products (1)

BENLYSTA (belimumab) for injection, 400 mg/20 mL vial, Rx only, NDC 49401-102-01, GSK.

BENLYSTA · 3 Vials

NDC: 49401-088, 49401-102, 49401-101, 49401-102-01, 49401-101-01, 49401-088-42, 49401-088-47, 49401-088-50, 49401-088-01, 49401-088-35, 49401-088-02, 49401-088-61
Lot codes: YK4W
Code info: Lot: YK4W, Expiration date: 4/30/2029

Affected areas

FloridaOhioVirginia

Timeline

  1. Initiated
    Apr 21, 2025
  2. Published
    Jul 30, 2025
Recall number
D-0540-2025
Agency
U.S. Food and Drug Administration
Country
US
Source data (openFDA JSON) About FDA enforcement reports

FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.